The Trentonian

Novartis receives FDA approval of Xolair(R) (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...
Business Wire

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Seeking Alpha

FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies

XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In people with asthma, CRSwNP and food allergy, a blood test for a substance called IgE must be ...
Monthly Prescribing Reference

FDA to Review Omalizumab Prefilled Syringe for Self-Administration

The FDA is expected to make a decision by the first quarter of 2021. The Food and Drug Administration (FDA) has accepted for filing the supplemental Biologics License Application (sBLA) for a new self ...
Nasdaq

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...